Derrick Gingery

An interesting @PharmaPinkSheet story on a lesser-known cut at @HHSGov: Elegy For SACHRP: US HHS Research Protection Panel Tackled Tough Pediatric Trial Questions https://t.co/B7eDl6wUKi

The latest @PharmaPinkSheet podcast is posted! Listen as @PinkSheetSutter, @SarahKarlin, @PinkSheetHobbs and I discuss CBER Director Vinay Prasad's comments about staying out of app reviews and the cuts in the @US_FDA budget proposal. NO PAYWALL!: https://t.co/rwTe7piEAl

Wonder if this will resonate as well ... @PharmaPinkSheet @RPMReportMike: Cell/Gene Therapy Cost Recovery Options Could Include Pre-Approval Public ‘Bridge’ Funding https://t.co/FM2sS1Jqg1

An interesting development, @PharmaPinkSheet's @PinkSheetSutter reports. Also note user fees are higher than non-user fee dollars, which is rare: House Gives US FDA More Non-User Fee Funds Than Requested https://t.co/2mBkxsk9OM

Wondering how @US_FDA officials will react to this idea. The @PharmaPinkSheet's @SarahKarlin reports on ensuring US cell and gene therapy leadership: To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says https://t.co/D6ObHHDgoP

RT @DrMakaryFDA: The pathway to improving patient access to safe and effective therapies starts with listening. Today FDA kicked off its Ph…

Sec. Kennedy, CMS Admin Oz, NIH director are at the @US_FDA cell and gene therapy mtg and will speak after 10 minute break.

The @US_FDA is really trying to get through intro comments at cell and gene therapy mtg because Secretary Kennedy is coming. Just asked remaining speakers to skip thank yous and so forth.

At the @US_FDA cell and gene therapy mtg. Have to say have not seen great room set up this way. There is special lighting, multiple cameras and a photographer to assist in the recording.

RT @SarahKarlin: Makary's & Trump may not see eye-to-eye on what "right to try" means. Thought his remarks were notable: "We want to give…

Another in a series of @PharmaPinkSheet stories on the EU reaction to the US most favored nation pricing policy: US ‘Most Favored Nations’ Drug Pricing Policy Will Jeopardize Innovation In Europe https://t.co/wLwJ2YIiBz

An interesting read about a non-profit trying to improve access to clinical trials from @PharmaPinkSheet's @PinkSheetSutter: Clinical Trials Nonprofit Fights for Access Despite DEI Crack-Down https://t.co/3SpemM2zeA

Is the death spiral coming or should MedPAC wait to see whether CMS fixes work before recommending other changes? @PharmaPinkSheet @RPMReportMike: Saving Part D: US Medicare Advisors Sound The Alarm https://t.co/EpBQgS443O

Having to specifically say this in public is a strong statement of the current times. A @PharmaPinkSheet report from @SarahKarlin: Prasad Says Involvement In US FDA Product Approvals Will Mirror Prior CBER Directors https://t.co/ujBkz3Iko9

After months of not posting any generic drugs program data, the @US_FDA dumps three-month's worth! https://t.co/Bdy7AMWVxv

Congrats to my @PharmaScrip colleages!

Citeline @Citeline

Congratulations to our Scrip team for winning a National Gold Award for data journalism in the American Society of Business Publication Editors' Azbee Awards! This underscores the power of @Citeline data — not to mention the caliber of our journalists. https://t.co/0w5wtLuPxK

The @US_FDA thinking may have changed, meaning stalled programs could be revived, @PharmaPinkSheet's @SarahKarlin reports: US FDA Cell-Gene Therapy Head Says Agency Has Revived Stalled Programs https://t.co/oCvDtpVsPd